# Is KLOW FDA Approved? Regulatory and Research-Only Status of the KLOW peptide

> Is KLOW FDA approved? No — neither the KLOW peptide blend nor any of its four components is FDA-approved. BPC-157 is in 503A category 2 and TB-500 is WADA-prohibited.

The plain regulatory record for the blend and each of its four components — FDA standing, the BPC-157 503A review, and the WADA listing of TB-500.

## The short version

Is KLOW FDA approved? No. Neither the KLOW blend nor any of its four ingredients is approved by the FDA for human use. KLOW is supplied for laboratory research only — not formulated, labeled, or intended for people. Each ingredient has its own regulatory footnote, but none of them adds up to approval. GHK-Cu shows up in cosmetics applied to the skin. BPC-157 was placed by the FDA in 'category 2' of a review of bulk substances pharmacies can compound — a flag, not an endorsement. TB-500 carries an extra layer for athletes: thymosin beta-4 is on the World Anti-Doping Agency banned list. And because the four-peptide combination has never been studied in a trial, no regulator has anything to approve. This page lays the record out, component by component, with sources.

## Is KLOW FDA approved?

No. Neither KLOW nor any of its four components is FDA-approved for human use [8]. GHK-Cu appears in topical cosmetics; BPC-157 was placed by the FDA in category 2 of its 503A bulk-substances review, meaning significant safety questions were identified for compounding use; and the blend as a whole is a research-only co-formulation with no approved or pharmacopeial combination product anywhere [1]. 'Research use only' is exactly what it says — the material is not labeled or intended for human or veterinary administration.

## Why an untested combination cannot be approved

Approval rests on controlled human evidence of safety and efficacy for a defined product. The four-peptide KLOW blend has none: no controlled in-vivo or human study has tested it against monotherapy, any subset, or placebo [1]. Recent expert reviews reinforce the standing — a 2026 Sports Medicine review of approved and unapproved peptide therapies (listing TB-500 and BPC-157) concluded that many unapproved peptides show favorable animal-model results but scarce rigorous human safety data and operate largely outside regulatory oversight [8], and a 2025 BPC-157 narrative review judged the human evidence extremely limited and urged that the compound be considered investigational [18]. An untested mixture is, by definition, not an approvable product.

## The WADA status: TB-500 is prohibited

For anyone in tested sport, the most consequential regulatory fact is anti-doping, not the FDA. TB-500 is the synthetic fragment of thymosin beta-4, and thymosin beta-4 is named on the WADA Prohibited List under S2 (peptide hormones and growth factors), banned at all times — in and out of competition [8][9]. Because TB-500 is one of KLOW's four components, the blend implicates anti-doping rules in any athletic context, regardless of the user's intent. This sits alongside the FDA non-approval as the second hard regulatory line on the page.

## The plain status, summarized

Put together, the regulatory record is short and consistent. FDA-approved: no, for the blend and for all four components. BPC-157: 503A category 2 in the FDA compounding review. TB-500/thymosin beta-4: WADA-prohibited at all times. Controlled blend study on record: none [1][8][9]. GHK-Cu's clearest legitimate footprint is in topical cosmetics, not systemic medicine [4]. For the safety reasoning behind these statuses, see [KLOW peptide side effects](/side-effects); for the underlying studies, see the [research references](/references). None of this is legal advice; it is a plain reading of the public regulatory record.

---

A calm, plain-English reading of the four-peptide KLOW record — each ingredient's studies surfaced gently and the untested blend named as the honest gap it is, with no clinic behind the page and nothing here dosed or sold.